Conditionally Active Biologics™ (CAB)
BioAtla®’s revolutionary patented platform for developing conditionally active therapeutics yields antibodies (as well as other biologics) that can be activated or inactivated under defined physiological conditions.
CAB technology takes advantage of the unique microenvironment associated with different diseases and tissues, which can result for example from differences in metabolism between diseased and normal tissue. For example, in cancer the unique cell metabolism described by Warburg contributes to a characteristic microenvironment that activates our antibodies when they are in close proximity to a tumor, and reversibly inactivates our antibodies if they drift away from the tumor.
- The unique physiology and metabolism of a diseased tissue is used to locally activate a biologic, even if its target is also found in normal tissue
- Activation of the biologic is reversible, such that it can be inactivated and reactivated as it passes from diseased to normal to diseased tissue
- No exogenous (for example non-antibody) sequence is introduced
- Can be applied to antibody therapeutics including naked antibodies and ADC’s, cell therapies such as CAR-T, enzyme therapies, or other biologics
4th Generation Antibody Therapeutics
Strong IP Protection
- 474 patents (254 issued / 7 allowed) patents and 213 patent applications cover BioAtla’s CAB technology and products
- Worldwide patent coverage with issued and pending applications in all major market/manufacturing countries
Broad patent coverage of including:
- Methods of making and screening CAB antibodies
- Different formats (e.g. ADC, multi-&-bi-specific, CAR-T, mAbs and proteins
- Specific antibodies (composition of matter)
- Broad coverage provides a patent minefield where the product is not dependent on a single patent for protection